Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680282 | 0.83 | MAPT (0.40) | TSHRMAPTCACNA1BAPBA1 | |
| Water SCHEMBL10920602 | 0.82 | MAPT (0.39) | TSHRMAPTCACNA1BAPBA1 | |
| Glycinebetaine SCHEMBL14779932 | 0.81 | TSHR (0.40) | BBOX1TSHRMAPTCACNA1BAPBA1 | |
| Glycinebetaine SCHEMBL3811070 | 0.79 | RAD52 (0.31) | TSHR | |
| Glycinebetaine SCHEMBL5682310 | 0.79 | CHRM5 (0.38) | BBOX1TSHRMAPTCACNA1BAPBA1 | |
| Glycinebetaine SCHEMBL16020999 | 0.78 | TSHR (0.39) | BBOX1TSHRMAPTCACNA1BAPBA1 | |
| Glycinebetaine SCHEMBL28199995 | 0.78 | TDP1 (0.36) | BBOX1TSHRMAPTCACNA1BAPBA1 | |
| Glycinebetaine SCHEMBL8692847 | 0.77 | TSHR (0.31) | BBOX1TSHR | |
| Glycinebetaine SCHEMBL23068097 | 0.77 | BBOX1 (0.38) | BBOX1TSHR | |
| Glycinebetaine SCHEMBL15228159 | 0.75 | CHRM5 (0.35) | BBOX1TSHRMAPTCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495489-B1 | CATALYST COMPONENT CONTAINING TITANIA FIBER, GLASS FIBERS AND A RESIN SUCH AS A FLUORORESIN; RETAINS ACTIVITY FOR EXTENDED PERIOD; REDUCTION OF NITROGEN OXIDES, OXIDATION OF ORGANIC SUBSTANCES AND DECOMPOSITION OF DIOXIN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-17 | — | — | US | claimed |
| WO-2024143154-A1 | ANTIMICROBIAL PEPTIDE AND METHOD FOR PRODUCING SAME | 住友化学株式会社 | 2024-07-04 | — | — | WO | disclosed |
| EP-1600143-B1 | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | HAYASHIBARA CO (JP) | 2019-07-10 | — | — | EP | disclosed |
| EP-2436383-B1 | ORAL MEDICINAL COMPOSITION AND ORAL MEDICINAL CAPSULE HAVING THE COMPOSITION ENCAPSULATED THEREIN | MORISHITA JINTAN CO (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-3143983-A1 | EXTERNAL DERMATOLOGICAL FORMULATION COMPRISING SACCHARIDE DERIVATIVE OF ALPHA, ALPHA-TREHALOSE | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2017-03-22 | — | — | EP | disclosed |
| EP-1731134-B1 | FUNCTIONAL POWDERS | HAYASHIBARA CO (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-8841261-B2 | Functional powdery product | Hayashibara Co., Ltd. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8202927-B2 | Near-infrared absorbing composition and near-infrared absorbing filter | DAI NIPPON PRINTING CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120093925-A1 | ORAL MEDICINAL COMPOSITION AND ORAL MEDICINAL CAPSULE HAVING THE COMPOSITION ENCAPSULATED THEREIN | MORISHITA JINTAN CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| CN-101351265-B | Thermal expansion microspheres and hollow fine particles, process for producing them, and assembly of tire and rim | BRIDGESTONE CORP | 2012-01-25 | — | — | CN | disclosed |
| EP-1731134-A1 | FUNCTIONAL POWDERS | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1621591-A1 | WATER BASE INK AND METHOD FOR FORMING IMAGE AND RECORDED IMAGE USING SAID INK | Canon Kabushiki Kaisha (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1600143-A1 | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20050130063-A1 | Composition for light-scattering film and light-scattering film using the same | TOYO INK MFG. CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050088501-A1 | Water-based ink, and image formation method and recorded image using the ink | CANON KABUSHIKI KAISHA (JP) | 2005-04-28 | — | — | US | disclosed |
| US-20030215572-A1 | Process for preparing composite particles | KAO CORPORATION (JP) | 2003-11-20 | — | — | US | disclosed |
| US-6518345-B2 | Flame resistance, fuel resistance and reignition prevention for both non-polar solvent fires and polar solvent fires, and also stability as a diluted solution, performance | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-1275417-A1 | Fire extinguishing composition | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-20020014610-A1 | Fire extinguishing composition | DAINIPPON INK AND CHEMICALS, INC. | 2002-02-07 | — | — | US | disclosed |
| EP-0774247-A2 | Hair care products | Ajinomoto Co., Inc. (JP) | 1997-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093925-A1 | ORAL MEDICINAL COMPOSITION AND ORAL MEDICINAL CAPSULE HAVING THE COMPOSITION ENCAPSULATED THEREIN | MUC1, TAS2R45, LIPA | BBOX1 3948/4885TSHR 4044/4885MAPT 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.